Loading...
01/09 22:53
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call summary highlights strong financial performance, including record revenue and operating profit growth, alongside optimistic guidance for fiscal 2025. Despite some concerns about Medicare Part B MFN impact and a slowdown in the 3PL business, management's overall outlook remains positive. The planned share repurchase and strategic growth initiatives, such as the acquisition of PRISM Vision, further bolster the positive sentiment. The Q&A section did not reveal significant risks, and management's responses suggest confidence in mitigating potential challenges. These factors collectively indicate a positive stock price movement over the next two weeks.
Full-year consolidated revenues $359 billion, up 16% year-over-year, driven by strong operational performance and strategic acquisitions.
Adjusted earnings per diluted share $33.05, up 20% year-over-year, exceeding long-term growth targets due to operational growth and a lower share count.
Cash returned to shareholders $3.5 billion, reflecting strong cash flow generation and disciplined capital deployment.
Fourth quarter consolidated revenue $90.8 billion, up 19% year-over-year, led by growth in the U.S. pharmaceutical segment.
Fourth quarter gross profit $3.4 billion, up 2% year-over-year, supported by specialty distribution and provider growth.
Fourth quarter operating expenses $1.9 billion, down 10% year-over-year, due to divestitures and cost optimization initiatives.
Fourth quarter operating profit $1.6 billion, up 24% year-over-year, benefiting from growth across all operating segments.
Interest expense $40 million, a decrease year-over-year due to effective cash and portfolio management.
Fourth quarter diluted earnings per share $10.12, up 64% year-over-year, driven by lower effective tax rate and strong operational growth.
Fourth quarter U.S. Pharmaceutical revenues $83.2 billion, up 21% year-over-year, driven by increased prescription volumes and specialty product distribution.
Fourth quarter Prescription Technology Solutions revenues $1.3 billion, up 13% year-over-year, reflecting increased prescription transaction volumes.
Fourth quarter Medical Surgical Solutions revenues $2.9 billion, up 1% year-over-year, driven by higher volumes of specialty pharmaceuticals.
Fourth quarter International revenues $3.5 billion, down 2% year-over-year, due to divestiture of Canada-based businesses.
Free cash flow $7.5 billion in the fourth quarter, driven by strong operating results and timing shifts.
Full-year operating profit $5.6 billion, up 15% year-over-year, led by growth in U.S. pharmaceutical and prescription technology segments.
Full-year free cash flow $5.2 billion, reflecting strong cash flow generation and working capital management.
Total cash and cash equivalents at quarter-end $5.7 billion, with total liquidity of approximately $10 billion.
Weighted average diluted shares outstanding 125.9 million, down 4% year-over-year, contributing to EPS growth.
Operating profit from Prescription Technology Solutions $285 million, up 34% year-over-year, driven by increased demand for access solutions.
Operating profit from Medical Surgical Solutions $285 million, up 15% year-over-year, reflecting operational efficiencies from cost optimization initiatives.
Operating profit from International segment $102 million, up 9% year-over-year, driven by higher pharmaceutical distribution volumes.
Corporate expenses $165 million, down 15% year-over-year, due to lower environmental reserve and higher interest income.
Return on invested capital 26%, more than doubled over the past five years, reflecting disciplined capital deployment.
Acquisitions in Oncology and Ophthalmology: Completed acquisition of a controlling interest in PRISM Vision and pending acquisition of Core Ventures to enhance community-based care.
Oncology Network Expansion: U.S. Oncology Network grew to over 2,700 providers across 645 sites, with an expected addition of 530 providers from Core Ventures.
Prescription Technology Solutions Growth: Delivered strong growth in access and affordability solutions, helping patients save over $10 billion on medications.
Market Positioning in Oncology: Strengthened position in community-based oncology care through strategic acquisitions and partnerships.
International Market Strategy: Continued divestiture of non-core international businesses, focusing on Canadian distribution and exiting European markets.
Operational Efficiencies: Achieved approximately $100 million in cost savings through optimization initiatives in the medical surgical segment.
Technology Investments: Invested in technology and automation to enhance operational efficiencies and customer service.
Separation of Medical Surgical Segment: Announced intent to separate the medical surgical segment into an independent company to enhance focus and capital deployment.
Long-term Growth Targets: Reaffirmed long-term adjusted earnings growth target of 12% to 14%.
Regulatory Issues: The company faces uncertainties in policies and macroeconomic conditions that could impact business planning decisions.
Supply Chain Challenges: The company emphasizes the importance of a strong sourcing program through a broad supplier base to maintain consistent product availability.
Competitive Pressures: The healthcare landscape is evolving rapidly, requiring the company to empower employees with tools and resources to drive innovation and improve efficiency.
Economic Factors: The company acknowledges dynamic market environments and the potential impact of economic conditions on its operations.
Divestitures: The company has undertaken several divestitures, including the Canadian retail business, to focus on strategic growth areas, which may pose risks during transitions.
Acquisition Risks: The pending acquisition of Core Ventures for approximately $2.49 billion carries risks related to integration and regulatory approvals.
Strategic Acquisitions: Completed acquisition of a controlling interest in PRISM Vision and pending acquisition of Core Ventures to enhance capabilities in Oncology and other specialties.
Oncology Network Growth: U.S. Oncology Network welcomed two new practices, growing total provider count to over 2,700 across 645 sites.
Technology and Automation Initiatives: Launched initiatives to modernize the enterprise using technology, automation, and AI to improve operational efficiencies.
Medical Surgical Segment Separation: Announced intent to separate the medical surgical segment into an independent company to enhance focus and capital deployment.
Fiscal 2026 Revenue Growth: Anticipate revenue growth of 11% to 15%.
Fiscal 2026 Operating Profit Growth: Expect operating profit growth of 8% to 12%.
Fiscal 2026 EPS Guidance: Projected earnings per diluted share of $36.75 to $37.55, representing 11% to 14% growth year-over-year.
Free Cash Flow: Anticipate free cash flow of approximately $4.4 billion to $4.8 billion.
Share Repurchase: Plans to repurchase approximately $2.5 billion of shares in fiscal 2026.
Dividends Paid: $345 million in dividends were paid to shareholders in fiscal 2025.
Share Repurchases: $3.1 billion was returned to shareholders through share repurchases in fiscal 2025.
Future Share Repurchase Plan: McKesson anticipates repurchasing approximately $2.5 billion of shares in fiscal 2026.
Total Cash Returned to Shareholders: McKesson returned a total of $3.5 billion to shareholders in fiscal 2025.
Total Cash Returned Since Fiscal 2020: Approximately $18 billion has been returned to shareholders through share repurchases and dividends since the beginning of fiscal 2020.
Reduction in Shares Outstanding: Total shares outstanding have been reduced by 34% since the beginning of fiscal 2020.
The earnings call summary indicates strong financial performance with raised guidance, robust revenue and operating profit growth, strategic acquisitions, and shareholder returns through share repurchases and dividend hikes. The Q&A section highlights positive analyst sentiment, with strong specialty volume trends and effective margin management. Despite some nonrecurring gains and vague responses, the overall sentiment remains positive. The raised guidance and strategic initiatives suggest a likely stock price increase, making a positive rating appropriate.
The earnings call presents a mixed picture. While there are positive aspects like raised revenue guidance and strategic acquisitions, there are concerns such as negative free cash flow and management's vague responses on long-term strategies and impacts of MSN. The Q&A section highlights stable performance but lacks strong catalysts for immediate growth. Overall, the sentiment is balanced by positive and negative elements, leading to a neutral prediction for stock price movement.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
